German vendor claims lead in global MRI salesThomas Miller's star continues to rise at Siemens. The outspokenexecutive is returning to the U.S. after two years in Germanyas group manager of MRI. Miller's promotion was announced at thismonth's
Thomas Miller's star continues to rise at Siemens. The outspokenexecutive is returning to the U.S. after two years in Germanyas group manager of MRI. Miller's promotion was announced at thismonth's Radiological Society of North America meeting.
Miller's new position, group vice president of imaging systems,includes operational responsibilities once held by Robert Dumke,president and CEO of Siemens Medical Systems of Iselin, NJ. Dumkehas been promoted to the managing board of Siemens Medical EngineeringGroup in Erlangen, Germany.
Dumke is the first American to serve on the three-person board,which includes Erich R. Reinhardt, chairman of the medical engineeringgroup, and Goetz Steinhardt, CFO of the group. Dumke replacesPeter Grassmann, who is leaving Siemens to take a position aschief executive of the German optical firm Zeiss.
Dumke will retain his position as head of Siemens' U.S. subsidiary.Much of the day-to-day control over operations in the imagingsystems group will fall to Miller, however. Miller will overseeU.S. operations of all modalities that do not have a U.S.-basedmanufacturing plant, including MRI, CT, mammography, x-ray andPACS. Lothar Koob will continue as head of Siemens Ultrasound,Thomas Cafarella as head of Siemens Nuclear Medicine and Pat Boyleas chief of Siemens Oncology Care Systems. All three report toDumke.
Miller was sent to Erlangen in 1992 as the first American namedto lead the vendor's worldwide MRI operations (SCAN 6/3/92). Histenure saw Siemens introduce Magnetom Vision, the first 1.5-teslaMRI scanner with 25 millitesla/meter actively shielded gradientcoils, and Magnetom Open, an open-configuration MRI scanner widelyimitated at this year's RSNA conference.
In 1992 Miller claimed that Siemens' 1-tesla Magnetom Impactscanner had become the best-selling magnet in the world (SCAN12/16/92). This year, he was prepared to go one better: Siemenshas overtaken GE as the market leader in worldwide MRI sales asmeasured by dollar volume, he said.
"It was very pleasing to us," Miller told SCAN. "GeneralElectric held the leadership position for quite some time. Itwas a long battle."
GE executives refuted Miller's claim to MRI ascendancy. Neithercompany is willing to provide the financial data necessary toprove which is king of the MRI hill, however.
Miller did say that Siemens' market share in the U.S. now standsat 32% and in Europe at 50%, measured by value as opposed to unitshipments. In Japan, Siemens is in the number two position. Mostof the market share Siemens has been taking has come from GE,he said.
The many works-in-progress MRI scanners on the exhibit floorof this year's RSNA show were testament to Siemens' lead in thetechnology, he said.
"There are more MRI systems at this show that are notavailable for delivery or FDA-approved than any time since 1983,"Miller said. "We forced (the other vendors) to do it. Let'sface it -- we are delivering Opens. If at this RSNA the otherguys didn't show Opens, we'd scoop a whole year's worth of market."
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.